<p>Ronapreve is a medicine used for treating COVID-19 in adults, adolescents and children from 2 years of age and weighing at least 10 kilograms, who do not require supplemental oxygen and who are at increased risk of their disease becoming severe.</p><p>Ronapreve is also used for treating COVID-19 in adults and adolescents from 12 years of age (weighing at least 40 kilograms) who are receiving supplemental oxygen and who have a negative SARS-CoV-2 antibody test result.</p><p>The medicine can also be used to prevent COVID-19 in people aged 12 years and older weighing at least 40 kilograms.</p><p>Ronapreve contains two active substances, casirivimab and imdevimab.</p><p>The medicine should be used in accordance with official recommendations, where available, and based on information on the activity of casirivimab and imdevimab against circulating viral variants. </p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Ronapreve is indicated for:<br>- Treatment of COVID-19 in adults, adolescents and children aged 2 years and older weighing at least 10 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.<br>- Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg and receiving supplemental oxygen, who have a negative SARS-CoV-2 antibody test result. <br>- Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.<br><br>Ronapreve should be used in accordance with official recommendations where available and based on information on the activity of casirivimab and imdevimab against presently circulating viral variants.</p></div>
Therapeutic Area (MeSH)
ATC Code
J06BD07
ATC Item
N/A
Pharmacotherapeutic Group
Immune sera and immunoglobulins
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| casirivimab | N/A | casirivimab |
| imdevimab | N/A | imdevimab |
EMA Name
Ronapreve
Medicine Name
Ronapreve
Aliases
N/ANo risk management plan link.
